Illumina Inc (ILMN) 167.90 $ILMN Illumina to We
Post# of 273323
Posted On: 09/03/2016 1:10:53 PM
Illumina Inc (ILMN) 167.90 $ILMN
Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Aug 30, 2:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it will webcast the company's presentation at the Morgan Stanley Global Healthcare Conference in New York, NY, on September 13, 2016. The live webcast is scheduled to begin at 1:30 PM ET and will feature a brief overview of the company by Marc Stapley, Executive Vice President, Chief Administrative Officer and Chief Financial Officer, followed by a question and answer session.
ILMN: 167.90 (-0.66), MS: 31.89 (-0.02)
Illumina Keen on Genome Network Growth & Global Expansion
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 2:23PM CDT
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
HSKA: 52.49 (-0.27), ILMN: 167.90 (-0.66), ANIK: 47.89 (-0.05)
Stock Market News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:55AM CDT
Benchmarks ended in the red on Wednesday following decline in Mylan’s shares, which had a negative impact on the biotech stocks and eventually on the broader healthcare sector
FIT: 14.96 (+0.01), ENDP: 19.82 (-0.41), VRTX: 95.11 (+0.36), GILD: 76.89 (-0.53), CEO: 123.29 (+2.65), MYL: 39.97 (-1.95), ILMN: 167.90 (-0.66), SDRL: 2.42 (+0.09), HPQ: 14.49 (-0.01), PVH: 108.56 (+0.38)
Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 82.73 (+0.45), TMO: 151.18 (+0.23), QDEL: 21.58 (-0.16), ILMN: 167.90 (-0.66)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Tue Aug 23, 3:08AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Buy to Neutral at CL King today. The stock closed yesterday at $173.75 on volume of 1.2 million shares, below average daily volume of 1.8 million. Illumina has overhead space with shares priced $173.75, or 1.4% below the average consensus analyst price target of $176.15. The stock should discover initial support at its 200-day moving average (MA) of $170.95 and subsequent support at its 50-day MA of $154.30.
ILMN: 167.90 (-0.66)
Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics
BusinessWire - Wed Aug 10, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina's Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.
BIO: 151.14 (+1.65), ILMN: 167.90 (-0.66)
Personal Genome Diagnostics To Collaborate With Illumina On Development Of Cancer In Vitro Diagnostic Test Kits
PR Newswire - Mon Aug 08, 6:30AM CDT
Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced an agreement with Illumina, Inc. (NASDAQ: ILMN) to develop two in-vitro diagnostic (IVD) test kits for use on Illumina's sequencing instruments, including kits for the detection and characterization of tumor DNA using both tissue and plasma samples.
ILMN: 167.90 (-0.66)
Learn how to target a 20% return on GoPro, or get option-trade ideas on Barrick Gold Corporation, Illumina, Ball Corporation and Intel or any stock you choose
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, BLL, GPRO, ILMN, and INTC.
GPRO: 14.13 (-0.40), ABX: 18.16 (+0.36), BLL: 80.66 (+0.81), ILMN: 167.90 (-0.66), INTC: 36.08 (+0.06)
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.97% Gain
Comtex SmarTrend(R) - Mon Aug 01, 2:06PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Illumina Set to Possibly Pullback After Yesterday's Rally of 1.97%
Comtex SmarTrend(R) - Mon Aug 01, 2:04PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Company News for July 28, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:10AM CDT
Companies In The News are: TWTR,APC,CB,ILMN
ILMN: 167.90 (-0.66), CB: 127.81 (+0.71), TWTR: 19.55 (+0.05), APC: 56.49 (+2.95)
Illumina Names Philip W. Schiller to its Board of Directors
BusinessWire - Thu Jul 28, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) announced today that Philip W. Schiller has joined the company's Board of Directors. Schiller is currently Apple's Senior Vice President of Worldwide Marketing and is a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs.
ILMN: 167.90 (-0.66)
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 117.43 (-0.20), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), ILMN: 167.90 (-0.66)
Illumina Rises 8.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 27, 12:14PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Illumina Set to Possibly Pullback After Yesterday's Rally of 8.29%
Comtex SmarTrend(R) - Wed Jul 27, 12:12PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Illumina, Inc. (ILMN) - Product Pipeline Market Analysis Report, 2016: Radiant Insights
GlobeNewswire - Thu Jun 23, 5:39AM CDT
Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations.
ILMN: 167.90 (-0.66)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), ILMN: 167.90 (-0.66), GHDX: 27.12 (+0.45)
Illumina Announces Initial Customer Orders for the Global Screening Array
BusinessWire - Thu Jun 16, 8:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium(R) Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.
ILMN: 167.90 (-0.66)
Watch for Illumina to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 2:51PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $139.41 to a high of $143.77. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.10 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 167.90 (-0.66)
Illumina Falls 1.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Jun 13, 2:49PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $139.41 to a high of $143.77. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.10 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 167.90 (-0.66)
Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Aug 30, 2:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it will webcast the company's presentation at the Morgan Stanley Global Healthcare Conference in New York, NY, on September 13, 2016. The live webcast is scheduled to begin at 1:30 PM ET and will feature a brief overview of the company by Marc Stapley, Executive Vice President, Chief Administrative Officer and Chief Financial Officer, followed by a question and answer session.
ILMN: 167.90 (-0.66), MS: 31.89 (-0.02)
Illumina Keen on Genome Network Growth & Global Expansion
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 2:23PM CDT
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
HSKA: 52.49 (-0.27), ILMN: 167.90 (-0.66), ANIK: 47.89 (-0.05)
Stock Market News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:55AM CDT
Benchmarks ended in the red on Wednesday following decline in Mylan’s shares, which had a negative impact on the biotech stocks and eventually on the broader healthcare sector
FIT: 14.96 (+0.01), ENDP: 19.82 (-0.41), VRTX: 95.11 (+0.36), GILD: 76.89 (-0.53), CEO: 123.29 (+2.65), MYL: 39.97 (-1.95), ILMN: 167.90 (-0.66), SDRL: 2.42 (+0.09), HPQ: 14.49 (-0.01), PVH: 108.56 (+0.38)
Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 82.73 (+0.45), TMO: 151.18 (+0.23), QDEL: 21.58 (-0.16), ILMN: 167.90 (-0.66)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Tue Aug 23, 3:08AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Buy to Neutral at CL King today. The stock closed yesterday at $173.75 on volume of 1.2 million shares, below average daily volume of 1.8 million. Illumina has overhead space with shares priced $173.75, or 1.4% below the average consensus analyst price target of $176.15. The stock should discover initial support at its 200-day moving average (MA) of $170.95 and subsequent support at its 50-day MA of $154.30.
ILMN: 167.90 (-0.66)
Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics
BusinessWire - Wed Aug 10, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina's Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.
BIO: 151.14 (+1.65), ILMN: 167.90 (-0.66)
Personal Genome Diagnostics To Collaborate With Illumina On Development Of Cancer In Vitro Diagnostic Test Kits
PR Newswire - Mon Aug 08, 6:30AM CDT
Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced an agreement with Illumina, Inc. (NASDAQ: ILMN) to develop two in-vitro diagnostic (IVD) test kits for use on Illumina's sequencing instruments, including kits for the detection and characterization of tumor DNA using both tissue and plasma samples.
ILMN: 167.90 (-0.66)
Learn how to target a 20% return on GoPro, or get option-trade ideas on Barrick Gold Corporation, Illumina, Ball Corporation and Intel or any stock you choose
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, BLL, GPRO, ILMN, and INTC.
GPRO: 14.13 (-0.40), ABX: 18.16 (+0.36), BLL: 80.66 (+0.81), ILMN: 167.90 (-0.66), INTC: 36.08 (+0.06)
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.97% Gain
Comtex SmarTrend(R) - Mon Aug 01, 2:06PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Illumina Set to Possibly Pullback After Yesterday's Rally of 1.97%
Comtex SmarTrend(R) - Mon Aug 01, 2:04PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $166.13 to a high of $170.88. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $167.03 on volume of 454,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Company News for July 28, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:10AM CDT
Companies In The News are: TWTR,APC,CB,ILMN
ILMN: 167.90 (-0.66), CB: 127.81 (+0.71), TWTR: 19.55 (+0.05), APC: 56.49 (+2.95)
Illumina Names Philip W. Schiller to its Board of Directors
BusinessWire - Thu Jul 28, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) announced today that Philip W. Schiller has joined the company's Board of Directors. Schiller is currently Apple's Senior Vice President of Worldwide Marketing and is a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs.
ILMN: 167.90 (-0.66)
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 117.43 (-0.20), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), ILMN: 167.90 (-0.66)
Illumina Rises 8.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 27, 12:14PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Illumina Set to Possibly Pullback After Yesterday's Rally of 8.29%
Comtex SmarTrend(R) - Wed Jul 27, 12:12PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $145.27 to a high of $163.08. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $152.33 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 167.90 (-0.66)
Illumina, Inc. (ILMN) - Product Pipeline Market Analysis Report, 2016: Radiant Insights
GlobeNewswire - Thu Jun 23, 5:39AM CDT
Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations.
ILMN: 167.90 (-0.66)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), ILMN: 167.90 (-0.66), GHDX: 27.12 (+0.45)
Illumina Announces Initial Customer Orders for the Global Screening Array
BusinessWire - Thu Jun 16, 8:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium(R) Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.
ILMN: 167.90 (-0.66)
Watch for Illumina to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 2:51PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $139.41 to a high of $143.77. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.10 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 167.90 (-0.66)
Illumina Falls 1.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Jun 13, 2:49PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $139.41 to a high of $143.77. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.10 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 167.90 (-0.66)
(0)
(0)